CRISPR disruption of PDCD1 (PD-1 KO) enhances cytolysis and tumor clearance in PD-L1+ models, establishing a generalizable blueprint for checkpoint gene editing in CAR T products (98). Here, PDCD1 is linked to neoplasm.